Nafamostat mesilate for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: A prospective, randomized, double-blind, controlled trial

Pancreas

Volumn 40, Issue 2, 2011, Pages 181-186

  Yoo, Kyo Sang ^a   Huh, Kyung Rim ^a   Kim, Yu Jin ^a   Kim, Kyoung Oh ^a   Park, Cheol Hee ^a   Hahn, Taeho ^a   Park, Sang Hoon ^a   Kim, Jong Hyeok ^a   Park, Choong Kee ^a   Kwon, Young Jun ^a   Lehman, Glen A ^b  

^a Hallym University College of Medicine   (South Korea)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

endoscopic retrograde cholangiopancreatography; nafamostat mesilate; pancreatitis; prevention

Indexed keywords

AMYLASE; MEGLUMINE IOXITALAMATE; MEGLUMINE IOXITALAMATE PLUS SODIUM IOXITALAMATE; NAFAMSTAT MESILATE; PLACEBO;

ADULT; AGED; AMYLASE BLOOD LEVEL; ARTICLE; BILE DUCT OBSTRUCTION; CLINICAL PROTOCOL; COMMON BILE DUCT STONE; CONTROLLED CLINICAL TRIAL; DEMOGRAPHY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; FACTUAL DATABASE; FEMALE; HUMAN; HYPERAMYLASEMIA; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PANCREAS ACINUS; PANCREAS CANCER; PANCREATITIS; PANCREATOBILIARY CANCER; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; VATER PAPILLA STENOSIS;

ADULT; AGED; CHI-SQUARE DISTRIBUTION; CHOLANGIOPANCREATOGRAPHY, ENDOSCOPIC RETROGRADE; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; GUANIDINES; HUMANS; INDIANA; INFUSIONS, INTRAVENOUS; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; PANCREATITIS; PROSPECTIVE STUDIES; PROTEASE INHIBITORS; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 79951724555     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPA.0b013e3181f94d46     Document Type: Article

References (38)

1. Masci E, Toti G, Mariani A, et al. Complications of diagnostic and therapeutic ERCP: a prospective multicenter study. Am J Gastroenterol. 2001;96:417-423.
2. Freeman ML, DiSario JA, Nelson DB, et al. Risk factors for post-ERCP pancreatitis: a prospective, multicenter study. Gastrointest Endosc. 2001;54:425-434. (Pubitemid 33661145)
3. Cheng CL, Sherman S, Watkins JL, et al. Risk factors for post-ERCP pancreatitis: a prospective multicenter study. Am J Gastroenterol. 2006;101:139-147. (Pubitemid 43381722)
4. Cavallini G, Tittobello A, Frulloni L, et al. Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography. Gabexate in digestive endoscopy - Italian Group. N Engl J Med. 1996;335:919-923. (Pubitemid 26314444)
5. Murray B, Carter R, Imrie C, et al. Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography. Gastroenterology. 2003;124:1786-1791. (Pubitemid 36666775)
6. Bai Y, Xu C, Yang X, et al. Glyceryl trinitrate for prevention of pancreatitis after endoscopic retrograde cholangiopancreatography: a meta-analysis of randomized, double-blind, placebo-controlled trials. Endoscopy. 2009;41:690-695.
7. Bang UC, Nojgaard C, Andersen PK, et al. Meta-analysis: nitroglycerin for prevention of post-ERCP pancreatitis. Aliment Pharmacol Ther. 2009;29:1078-1085.
8. Elmunzer BJ, Waljee AK, Elta GH, et al. A meta-analysis of rectal NSAIDs in the prevention of post-ERCP pancreatitis. Gut. 2008;57:1262-1267.
9. Poon RT, Yeung C, Lo CM, et al. Prophylactic effect of somatostatin on post-ERCP pancreatitis: a randomized controlled trial. Gastrointest Endosc. 1999;49:593-598. (Pubitemid 29227021)
10. Lee KT, Lee DH, Yoo BM. The prophylactic effect of somatostatin on post-therapeutic endoscopic retrograde cholangiopancreatography pancreatitis: a randomized, multicenter controlled trial. Pancreas. 2008;37:445-448.
11. Testoni PA. Pharmacological prevention of post-ERCP pancreatitis: the facts and the fiction. JOP. 2004;5:171-178. (Pubitemid 41573864)
12. Fujii S, Hitomi Y. New synthetic inhibitors of C1r, C1 esterase, thrombin, plasmin, kallikrein and trypsin. Biochim Biophys Acta. 1981;661:342-345. (Pubitemid 12233442)
13. Keck T. Site-specific therapeutic effects of protease inhibitors: effect of route of administration in experimental pancreatitis. Pancreatology. 2001;1:656-661. (Pubitemid 33674963)
14. Iwaki M, Ino Y, Motoyoshi A, et al. Pharmacological studies of FUT-175, nafamostat mesilate. V. Effects on the pancreatic enzymes and experimental acute pancreatitis in rats. Jpn J Pharmacol. 1986;41:155-162.
15. Otsuki M, Hirota M, Arata S, et al. Consensus of primary care in acute pancreatitis in Japan. World J Gastroenterol. 2006;12:3314-3323. (Pubitemid 43933774)
16. Choi CW, Kang DH, Kim GH, et al. Nafamostat mesylate in the prevention of post-ERCP pancreatitis and risk factors for post-ERCP pancreatitis. Gastrointest Endosc. 2009;69:e11-e18.
17. Cotton PB, Lehman G, Vennes J, et al. Endoscopic sphincterotomy complications and their management: an attempt at consensus. Gastrointest Endosc. 1991;37:383-393.
18. Chen CC, Wang SS, Lee FY. Action of antiproteases on the inflammatory response in acute pancreatitis. JOP. 2007;8:488-494.
19. Brust R, Thomson AB, Wensel RH, et al. Pancreatic injury following ERCP. Failure of prophylactic benefit of Trasylol. Gastrointest Endosc. 1977;24:77-79.
20. Andriulli A, Clemente R, Solmi L, et al. Gabexate or somatostatin administration before ERCP in patients at high risk for post-ERCP pancreatitis: a multicenter, placebo-controlled, randomized clinical trial. Gastrointest Endosc. 2002;56:488-495.
21. Andriulli A, Solmi L, Loperfido S, et al. Prophylaxis of ERCP-related pancreatitis: a randomized, controlled trial of somatostatin and gabexate mesylate. Clin Gastroenterol Hepatol. 2004;2:713-718. (Pubitemid 39013432)
22. Xiong GS, Wu SM, Zhang XW, et al. Clinical trial of gabexate in the prophylaxis of post-endoscopic retrograde cholangiopancreatography pancreatitis. Braz J Med Biol Res. 2006;39:85-90.
23. Manes G, Ardizzone S, Lombardi G, et al. Efficacy of postprocedure administration of gabexate mesylate in the prevention of post-ERCP pancreatitis: a randomized, controlled, multicenter study. Gastrointest Endosc. 2007;65:982-987. (Pubitemid 46783824)
24. Tsujino T, Komatsu Y, Isayama H, et al. Ulinastatin for pancreatitis after endoscopic retrograde cholangiopancreatography: a randomized, controlled trial. Clin Gastroenterol Hepatol. 2005;3:376-383. (Pubitemid 40488346)
25. Yoo JW, Ryu JK, Lee SH, et al. Preventive effects of ulinastatin on post-endoscopic retrograde cholangiopancreatography pancreatitis in high-risk patients: a prospective, randomized, placebo-controlled trial. Pancreas. 2008;37:366-370.
26. Masci E, Cavallini G, Mariani A, et al. Comparison of two dosing regimens of gabexate in the prophylaxis of post-ERCP pancreatitis. Am J Gastroenterol. 2003;98:2182-2186. (Pubitemid 37305356)
27. Tsujino T, Kawabe T, Omata M. Antiproteases in preventing post-ERCP acute pancreatitis. JOP. 2007;8:509-517. (Pubitemid 47263693)
28. Andriulli A, Leandro G, Niro G, et al. Pharmacologic treatment can prevent pancreatic injury after ERCP: a meta-analysis. Gastrointest Endosc. 2000;51:1-7. (Pubitemid 30051601)
29. Andriulli A, Leandro G, Federici T, et al. Prophylactic administration of somatostatin or gabexate does not prevent pancreatitis after ERCP: an updated meta-analysis. Gastrointest Endosc. 2007;65:624-632. (Pubitemid 46442832)
30. Fujishiro H, Adachi K, Imaoka T, et al. Ulinastatin shows preventive effect on post-endoscopic retrograde cholangiopancreatography pancreatitis in a multicenter prospective randomized study. J Gastroenterol Hepatol. 2006;21:1065-1069. (Pubitemid 43823296)
31. Ueki T, Otani K, Kawamoto K, et al. Comparison between ulinastatin and gabexate mesylate for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a prospective, randomized trial. J Gastroenterol. 2007;42:161-167. (Pubitemid 46404221)
32. Takeda K, Takada T, Kawarada Y, et al. JPN Guidelines for the management of acute pancreatitis: medical management of acute pancreatitis. J Hepatobiliary Pancreat Surg. 2006;13:42-47. (Pubitemid 43193673)
33. Imaizumi H, Kida M, Nishimaki H, et al. Efficacy of continuous regional arterial infusion of a protease inhibitor and antibiotic for severe acute pancreatitis in patients admitted to an intensive care unit. Pancreas. 2004;28:369-373. (Pubitemid 38509739)
34. Mori S, Itoh Y, Shinohata R, et al. Nafamostat mesilate is an extremely potent inhibitor of human tryptase. J Pharmacol Sci. 2003;92:420-423. (Pubitemid 37086724)
35. Keck T, Balcom JH, Antoniu BA, et al. Regional effects of nafamostat, a novel potent protease and complement inhibitor, on severe necrotizing pancreatitis. Surgery. 2001;130:175-181. (Pubitemid 32721666)
36. Freeman ML, Nelson DB, Sherman S, et al. Same-day discharge after endoscopic biliary sphincterotomy: observations from a prospective multicenter complication study. The Multicenter Endoscopic Sphincterotomy (MESH) Study Group. Gastrointest Endosc. 1999;49:580-586.
37. Hui CK, Lai KC, Wong WM, et al. Outpatients undergoing therapeutic endoscopic retrograde cholangiopancreatography: six-hour versus overnight observation. J Gastroenterol Hepatol. 2004;19: 1163-1168.
38. Freeman ML. Pancreatic stents for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis. Clin Gastroenterol Hepatol. 2007;5:1354-1365.